S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:XBIO - Xenetic Biosciences Stock Price, Forecast & News

$1.08
-0.04 (-3.57 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$1.04
Now: $1.08
$1.14
50-Day Range
$1.12
MA: $1.43
$1.69
52-Week Range
$0.93
Now: $1.08
$39.00
Volume517,600 shs
Average Volume601,424 shs
Market Capitalization$4.04 million
P/E RatioN/A
Dividend YieldN/A
Beta2.69
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIO
CUSIPN/A
CIKN/A
Phone781-778-7720

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.59 million
Book Value$12.65 per share

Profitability

Net Income$-7,300,000.00

Miscellaneous

Employees4
Market Cap$4.04 million
Next Earnings Date4/3/2020 (Estimated)
OptionableNot Optionable

Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.


Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) released its quarterly earnings data on Wednesday, November, 15th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.03. The company had revenue of $0.09 million for the quarter. View Xenetic Biosciences' Earnings History.

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Xenetic Biosciences.

What price target have analysts set for XBIO?

1 Wall Street analysts have issued twelve-month price objectives for Xenetic Biosciences' stock. Their forecasts range from $2.50 to $2.50. On average, they expect Xenetic Biosciences' share price to reach $2.50 in the next twelve months. This suggests a possible upside of 131.5% from the stock's current price. View Analyst Price Targets for Xenetic Biosciences.

What is the consensus analysts' recommendation for Xenetic Biosciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xenetic Biosciences.

Has Xenetic Biosciences been receiving favorable news coverage?

News coverage about XBIO stock has been trending very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xenetic Biosciences earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Xenetic Biosciences.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 145,500 shares, a decrease of 46.9% from the January 15th total of 273,900 shares. Based on an average trading volume of 548,700 shares, the days-to-cover ratio is presently 0.3 days. Currently, 3.1% of the company's shares are short sold. View Xenetic Biosciences' Current Options Chain.

Who are some of Xenetic Biosciences' key competitors?

What other stocks do shareholders of Xenetic Biosciences own?

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the folowing people:
  • Mr. Jeffrey F. Eisenberg, CEO & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.23%) and Oxford Asset Management LLP (1.46%).

Which major investors are buying Xenetic Biosciences stock?

XBIO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Oxford Asset Management LLP.

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $1.08.

How big of a company is Xenetic Biosciences?

Xenetic Biosciences has a market capitalization of $4.04 million and generates $7.59 million in revenue each year. Xenetic Biosciences employs 4 workers across the globe.View Additional Information About Xenetic Biosciences.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is http://www.xeneticbio.com/.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected]


MarketBeat Community Rating for Xenetic Biosciences (NASDAQ XBIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  155 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about Xenetic Biosciences and other stocks. Vote "Outperform" if you believe XBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel